For instance, there is higher ATP-binding cassette transporter expression in CD34+/CD38− AML cells compared with CD34+/CD38+ AML cells (3), and a subset of CD34+/CD38− cells is able to resist venetoclax by altering what substrates are used to fuel the tricarboxylic acid cycle and oxidative phosphorylation (4). Here, CD38 is linked to acute myeloid leukemia.